Equities

Observe Medical ASA

Observe Medical ASA

Actions
  • Price (EUR)0.021
  • Today's Change-0.006 / -22.22%
  • Shares traded0.00
  • 1 Year change-46.32%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Observe Medical ASA is a Norway-based medtech company that develops, markets and sells medtech products for the global market. The Company has a broad distribution portfolio of medtech devices and disposables, mainly within Urine measurement, Anesthesiology/ICUs and wound care. The Company is recognized for development and distribution of the Sippi automated digital urine system. Sippi is consist of several products like urine temperature catheters fixating devices to use in combination with urine catheters. Another product Biim is s approved for ultrasound imaging of the human body and is specifically used to guide needle and catheter insertions for dialysis and vascular access procedures. Observe Medical ASA is the parent company of its wholly owned subsidiaries, Observe Medical International AS, Observe Medical AB, Observe Medical ApS, Observe Medical Nordic AB and Biim Ultrasound AS.

  • Revenue in NOK (TTM)--
  • Net income in NOK--
  • Incorporated2019
  • Employees5.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.